MX386859B - Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos. - Google Patents
Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.Info
- Publication number
- MX386859B MX386859B MX2016010216A MX2016010216A MX386859B MX 386859 B MX386859 B MX 386859B MX 2016010216 A MX2016010216 A MX 2016010216A MX 2016010216 A MX2016010216 A MX 2016010216A MX 386859 B MX386859 B MX 386859B
- Authority
- MX
- Mexico
- Prior art keywords
- solid pharmaceutical
- receptor antagonists
- pharmaceutical compositions
- androgen receptor
- enzalutamide
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 3
- 229940123407 Androgen receptor antagonist Drugs 0.000 title abstract 2
- 239000003936 androgen receptor antagonist Substances 0.000 title abstract 2
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 abstract 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 abstract 1
- 229960004671 enzalutamide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14154047 | 2014-02-05 | ||
| PCT/EP2015/052311 WO2015118015A1 (en) | 2014-02-05 | 2015-02-04 | Solid pharmaceutical compositions of androgen receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016010216A MX2016010216A (es) | 2016-11-15 |
| MX386859B true MX386859B (es) | 2025-03-19 |
Family
ID=50031275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010216A MX386859B (es) | 2014-02-05 | 2015-02-04 | Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160346207A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3102183A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6666254B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20160113294A (cg-RX-API-DMAC7.html) |
| CN (2) | CN112402360A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015215000B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2940984A1 (cg-RX-API-DMAC7.html) |
| EA (2) | EA037895B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX386859B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015118015A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3305285T (lt) | 2012-09-26 | 2020-12-10 | Aragon Pharmaceuticals, Inc. | Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį |
| PL3226843T3 (pl) * | 2014-12-05 | 2021-12-13 | Aragon Pharmaceuticals, Inc. | Kompozycje przeciwnowotworowe |
| CN114886852A (zh) | 2014-12-05 | 2022-08-12 | 阿拉贡药品公司 | 抗癌组合物 |
| CA2969661C (en) * | 2014-12-05 | 2023-04-25 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| MX2018014846A (es) * | 2016-06-03 | 2019-03-14 | Aragon Pharmaceuticals Inc | Composiciones antineoplasicas. |
| WO2017221144A1 (en) * | 2016-06-20 | 2017-12-28 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
| CN110023297A (zh) * | 2016-07-08 | 2019-07-16 | 詹森药业有限公司 | 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物 |
| EP3500310A1 (en) | 2016-08-20 | 2019-06-26 | FTF Pharma Private Limited | Pharmaceutical composition comprising an androgen receptor inhibitor |
| KR102684756B1 (ko) * | 2017-04-28 | 2024-07-15 | 아스텔라스세이야쿠 가부시키가이샤 | 엔잘루타미드를 함유하는 경구 투여용 의약 조성물 |
| WO2019008426A1 (en) * | 2017-07-04 | 2019-01-10 | Bdr Pharmaceuticals International Private Limited | NOVEL ENZALUTAMIDE ORAL GALENIC FORM COMPOSITION AND METHOD OF MANUFACTURING THE SAME |
| WO2019016747A1 (en) * | 2017-07-20 | 2019-01-24 | Dr. Reddy's Laboratories Limited | AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION |
| RU2020109948A (ru) * | 2017-08-08 | 2021-09-10 | Др. Редди'З Лабораториз Лимитед | Экструдированные композиции энзалутамида |
| CZ2018234A3 (cs) | 2018-05-21 | 2019-12-04 | Zentiva Ks | Zvýšení rozpustnosti a biodostupnosti enzalutamidu |
| CN108815129A (zh) * | 2018-07-12 | 2018-11-16 | 天津双硕医药科技有限公司 | 一种恩杂鲁胺纳米晶体口服固体药物组合物 |
| ES2943492T3 (es) | 2018-11-30 | 2023-06-13 | Chemocentryx Inc | Formulación de cápsulas |
| JP2022533463A (ja) * | 2019-05-23 | 2022-07-22 | ヘルム・アクチエンゲゼルシャフト | エンザルタミドを含むナノ粒子 |
| EP4037659B1 (en) | 2019-10-03 | 2025-11-19 | Synthon BV | Pharmaceutical composition comprising enzalutamide |
| EP3811932A1 (en) | 2019-10-22 | 2021-04-28 | Zentiva K.S. | Dosage form of apalutamide |
| US20240207239A1 (en) * | 2021-02-06 | 2024-06-27 | Sunshine Lake Pharma Co., Ltd. | Composition and preparation method therefor |
| WO2024127361A1 (en) | 2022-12-16 | 2024-06-20 | Ferring B.V. | Enzalutamide nanocrystals, methods and compositions |
| WO2025052925A1 (ja) * | 2023-09-08 | 2025-03-13 | 沢井製薬株式会社 | エンザルタミド固体分散体及びその製造方法、並びにエンザルタミド含有製剤及びその製造方法 |
| WO2025125565A1 (en) | 2023-12-13 | 2025-06-19 | Krka, D.D., Novo Mesto | Tablet comprising enzalutamide |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2448825C (en) * | 2001-06-22 | 2009-08-11 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drug |
| CN102755318B (zh) * | 2006-03-29 | 2014-09-10 | 加利福尼亚大学董事会 | 二芳基硫代乙内酰脲化合物 |
| US9108944B2 (en) * | 2010-02-16 | 2015-08-18 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| EP2877599B1 (en) * | 2012-07-27 | 2019-10-23 | Aragon Pharmaceuticals, Inc. | Methods and compositions for determining resistance to androgen receptor therapy |
| DK3725778T3 (da) * | 2012-09-11 | 2021-09-20 | Medivation Prostate Therapeutics Llc | Formuleringer af enzalutamid |
-
2015
- 2015-02-04 AU AU2015215000A patent/AU2015215000B2/en not_active Ceased
- 2015-02-04 JP JP2016550203A patent/JP6666254B2/ja not_active Expired - Fee Related
- 2015-02-04 KR KR1020167023987A patent/KR20160113294A/ko not_active Ceased
- 2015-02-04 CA CA2940984A patent/CA2940984A1/en not_active Abandoned
- 2015-02-04 MX MX2016010216A patent/MX386859B/es unknown
- 2015-02-04 WO PCT/EP2015/052311 patent/WO2015118015A1/en not_active Ceased
- 2015-02-04 EP EP15702494.4A patent/EP3102183A1/en not_active Withdrawn
- 2015-02-04 CN CN202011306482.5A patent/CN112402360A/zh active Pending
- 2015-02-04 KR KR1020207003272A patent/KR20200015830A/ko not_active Ceased
- 2015-02-04 CN CN201580015541.4A patent/CN106102716A/zh active Pending
- 2015-02-04 EA EA201691568A patent/EA037895B1/ru unknown
- 2015-02-04 EA EA201891397A patent/EA201891397A1/ru unknown
- 2015-02-04 US US15/114,890 patent/US20160346207A1/en not_active Abandoned
-
2019
- 2019-12-27 JP JP2019238913A patent/JP6934932B2/ja not_active Expired - Fee Related
-
2020
- 2020-01-24 US US16/751,521 patent/US20200163882A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015215000B2 (en) | 2017-10-19 |
| EA201691568A1 (ru) | 2017-01-30 |
| EA201891397A1 (ru) | 2019-03-29 |
| MX2016010216A (es) | 2016-11-15 |
| KR20200015830A (ko) | 2020-02-12 |
| JP2017507928A (ja) | 2017-03-23 |
| CN112402360A (zh) | 2021-02-26 |
| AU2015215000A1 (en) | 2016-09-15 |
| JP6666254B2 (ja) | 2020-03-13 |
| CA2940984A1 (en) | 2015-08-13 |
| US20160346207A1 (en) | 2016-12-01 |
| JP6934932B2 (ja) | 2021-09-15 |
| CN106102716A (zh) | 2016-11-09 |
| JP2020090505A (ja) | 2020-06-11 |
| EP3102183A1 (en) | 2016-12-14 |
| WO2015118015A1 (en) | 2015-08-13 |
| US20200163882A1 (en) | 2020-05-28 |
| EA037895B1 (ru) | 2021-06-02 |
| KR20160113294A (ko) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX386859B (es) | Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos. | |
| ZA202004557B (en) | Modulatory polynucleotides | |
| IL261163B (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| PH12016502479A1 (en) | Formulated receptor polypeptides and related methods | |
| JO3512B1 (ar) | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز | |
| PH12016501791A1 (en) | Muscarinic receptor agonists | |
| PH12017500660A1 (en) | Novel compositions, uses and methods for making them | |
| EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
| TW201614041A (en) | Compositions for electronic devices | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| MY191590A (en) | 9h-pyrrolo-dipyridine derivatives | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| MX373324B (es) | Compuestos piridínicos de pladienolida y métodos de uso. | |
| MX2017012595A (es) | Un extracto de indigo naturalis y un proceso para preparar el mismo. | |
| MX379271B (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer. | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| CL2016001937A1 (es) | Compuestos de benzopirano funcionalizados y uso de los mismos | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| PH12017500853B1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
| PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| MX379126B (es) | Formulación de factor viii. | |
| MX384259B (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
| IN2014CH00840A (cg-RX-API-DMAC7.html) | ||
| IN2014MU00495A (cg-RX-API-DMAC7.html) | ||
| PH12017501147A1 (en) | Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs |